Tenet Healthcare beat the bearish hospital narrative and outdid HCA, posting a beat, a raised outlook and an additional $2 billion buyback. x.com 

Stryker's 10% post-earnings drop is unwarranted because the numbers were fine. Organic revenue was in line, margins beat, full-year guidance was reiterated and MedSurg is tracking to the high end of its range. Keeping guidance after a cyber incident, despite end-market callouts from Intuitive Surgical and HCA, should be positive. The stock is at its lowest multiple since 2015, derated from over 30x to 18x, with Mako and neurovascular strong; a collapse in hospital buying is the risk. x.com  x.com 

UnitedHealth's insurance model beats hospital operators like HCA because insurers get paid while hospitals see a good chunk of bills never paid or heavily reduced. Members must pay premiums to keep their benefits, and insurers don't pay claims until any deductible is met. That makes UnitedHealth attractive and HCA, along with the REITs that own hospitals, unattractive. x.com 

UnitedHealth's collapse was driven more by fear than fundamentals, making it one of the biggest opportunities in years, reminiscent of Meta in 2022. Fraud accusations led nowhere as the DOJ dropped its investigation, and peers Humana and CVS recovered from the same cost underestimation and beat later. With over $420B in revenue and deep ties to US employers, UnitedHealth is too big to fail and could survive even a fine. That same logic pointed to Berkshire being the undisclosed buyer. x.com 

UnitedHealth's rebound still has a Medicaid problem because care costs are outpacing state funding. Q3 operating profit rose to $6.6bn from $4.3bn a year earlier, but Medicaid is still expected to lose money in 2026. x.com 

Healthcare is the clearest place money is moving, and UnitedHealth is the preferred name here. It beat earnings and raised its 2026 profit forecast. x.com 

UnitedHealth's earnings visibility, unusually high dividend yield and resumed buybacks make paying under 16x forward earnings not look terrible. Still reasonably confident it is a good place to hide for long-term capital: Hemsley keeps clearing the bar, and UnitedHealth has beaten and raised guidance for three straight quarters. Further derisking remains a risk. x.com  x.com  x.com 

UnitedHealth and healthcare look set to outperform through year-end, helped by midterm-year seasonality and defensive appeal. Over the last 20 years healthcare has generally done well from July through December in midterm election years. If the S&P 500 rolls into a bear market, UnitedHealth could outperform as investors rotate into defensive sectors. The bull case holds if medical cost ratios fall from AI and GLP-1 use and institutions rotate back into healthcare. x.com 

UnitedHealth collects ever-rising US healthcare spending, and its stock has stopped falling. Family plan costs rose 249% in two decades toward $24,000, US spending nears $10,000 a person, and the over-65 population is set to double to two billion by 2050. After earnings fell 59% and 69% in back-to-back quarters and the stock dropped from 606 to 248, it based near 250 for a year, a Weinstein Stage 1, then reclaimed its moving average and pushed above 400. x.com  x.com  x.com  x.com 

Humana is showing a clean distribution top amid managed-care margin pressure. Elevance's margin miss hit the sector on July 15, Humana's Q1 adjusted EPS fell 11% on margin compression, and it is divesting its roughly $900M Gentiva stake. The chart shows a bearish engulfing candle, a volume surge, a trend break and RSI divergence; a close below the trigger line targets $372.70, then $356.38. x.com